Gilead Sciences, Inc. Market Research Report
Company Overview
Name and Mission of the Company
- Name: Gilead Sciences, Inc.
- Mission: To discover, develop, and deliver innovative therapeutics for people with life-threatening diseases. The company aims to create a healthier world for all people, with a strong focus on innovation and addressing health inequities.
Founding and Key People
- Founded: Gilead was established as Oligogen on June 22, 1987, and became Gilead Sciences one year later.
- Key People:
- Chairman and Chief Executive Officer: Daniel O’Day
- Chief Financial Officer: Andrew Dickinson
- Executive Vice President, Pharmaceutical Development and Manufacturing: Stacey Ma
- Executive Vice President, Research: Flavius Martin, MD
- Executive Vice President, Human Resources: Jyoti Mehra
- Chief Commercial Officer: Johanna Mercier
- Chief Medical Officer: Pending appointment of Dietmar Berger, MD, PhD, effective January 2, 2025
Headquarters
- Location: Foster City, California, United States
Number of Employees
- Employees: Over 18,000 globally
Revenue
- Information unavailable
Company Expertise
- Known For: Revolutionizing HIV treatment and prevention, providing a cure for hepatitis C, addressing public health challenges, and pursuing transformative therapies in virology, oncology, and inflammation.
Products
Product Portfolio
- Medicines Offered: More than 25 therapies are offered globally, particularly in areas of virology, oncology, and inflammation.
- Key Features:
- Gilead is recognized for its scientific innovation and transformative impacts in combating life-threatening diseases.
- The pipeline is diverse, focusing on transformative therapies to advance health equity.
Recent Developments
New Products and Features
- Twice-Yearly HIV Prevention Medication: Lauded as Science’s 2024 Breakthrough of the Year.
- Trodelvy (sacituzumab govitecan-hziy): Received Breakthrough Therapy Designation by the U.S. FDA for second-line treatment of extensive-stage small cell lung cancer.
- Seladelpar: Positive CHMP opinion for primary biliary cholangitis, with FDA accelerated approval in 2024.
Partnerships
- Collaboration with Terray Therapeutics: Focus on leveraging AI-driven drug discovery for novel small molecule therapies.
- Acquisition Activities:
- CymaBay: Acquisition approved, advancing treatment options for primary biliary cholangitis.
- Parsippany, New Jersey Hub: New facility for oncology innovation.
Leadership and Organization
- New Appointment: Dietmar Berger, MD, PhD, as the Chief Medical Officer starting January 2025.
Recent Achievements and Recognition
- Science’s Breakthrough of the Year: Recognition for innovations in HIV prevention.
- Kite's Yescarta CAR T-Cell Therapy: Demonstrated durable response and long-term survival after five years for non-Hodgkin lymphomas.
Note: This report is based solely on the information extracted from the provided data on Gilead Sciences, Inc. Some fields were marked "No information is available" due to lack of data.
